Update 1990 pp 121-127 | Cite as

Therapy of Septic Shock: New Strategies

  • R. C. Bone
  • R. C. Brown
Conference paper
Part of the Update in Intensive Care and Emergency Medicine book series (UICM, volume 10)

Abstract

The high frequency and often devastating consequences of sepsis make it a major cause of death from infection in the United States today [1]. Although bacteremia may be asymptomatic, it too often comes to clinical attention as an acute catastrophic event recognized by a characteristic constellation of signs and symptoms. Indeed, the term sepsis implies bacteremia coupled with a host response to the circulating microorganisms. Factors that determine the presence or absence of clinical symptoms are largely unknown, though they are of obvious importance in the therapy of bacteremic patients. Conversely, several clinical and laboratory features of bacteremic patients mitigate for or against survival and the development of a particularly devastating manifestation of sepsis, the adult respiratory distress syndrome (ARDS). This review will discuss risk factors, incidence, and prognostic indicators of sepsis and septic ARDS, and conclude with a brief review of two controversial aspects of therapy for septic lung injury: corticosteroids and prophylactic positive end expiratory pressure (PEEP).

Keywords

Placebo Lactate Corticosteroid Bacillus Angiotensin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    McCabe WR (1973) Gram negative bacteremia: Disease-a-month. Chicago, Year Book Medical PublishersGoogle Scholar
  2. 2.
    Sheagren JH (1986) Shock syndromes related to sepsis. Cecil Textbook of Medicine. Saunders, Philadelphia, pp 1473–1477Google Scholar
  3. 3.
    McCabe WR, Treadwell TL, Maria AD (1983) Pathophysiology of bacteremia. Am J Med 75:7–18PubMedCrossRefGoogle Scholar
  4. 4.
    National Heart, Lung, and Blood Institute (1979) Extracorporeal support for respiratory insufficiency: Collaborative study. National Heart, Lung, and Blood Institute, Washington, DCGoogle Scholar
  5. 5.
    Goldfarb RD, Tambolini W, Wiener SM, et al (1983) Canine left ventricular performance during LD50 endotoxemia. Am J Physiol 244:H370–H377PubMedGoogle Scholar
  6. 6.
    Kreger BEW, Craven DE, McCabe WR (1980) Gram-negative bacteremia: IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 68:344–355PubMedCrossRefGoogle Scholar
  7. 7.
    McCabe WR (1973) Serum complement levels in bacteremia due to gram negative organisms. N Engl J Med 288:21–23PubMedCrossRefGoogle Scholar
  8. 8.
    Winslow EJ, Loeb HS, Rahimtoola SH, et al (1973) Hemodynamic studies and results of therapy in 50 patients with bacteremic shock. Am J Med 54:421–432PubMedCrossRefGoogle Scholar
  9. 9.
    Hook EW, Horton CA, Schaberg DR (1983) Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. J Am Med Assoc 249:1055–1057CrossRefGoogle Scholar
  10. 10.
    Bone RC, Fisher CJ, Clemmer TP, et al (1989) The sepsis syndrome: a valid clinical entity. Crit Care Med 17:389–393PubMedCrossRefGoogle Scholar
  11. 11.
    Parker MM, Parillo JE (1983) Hemodynamics and pathogenesis. J Am Med Assoc 250:3324–3327CrossRefGoogle Scholar
  12. 12.
    Shubin H, Weil MH (1976) Bacterial shock. J Am Med Assoc 235:421–424CrossRefGoogle Scholar
  13. 13.
    Abraham E, Shoemaker WC, Bland RD, et al (1983) Plasma fibronectin in medical ICU patients. Crit Care Med 11:799–803PubMedCrossRefGoogle Scholar
  14. 14.
    Halushka PV, Reines HD, Barrow SE, et al (1985) Elevated 6-keto-prostaglandin Fla in patients in septic shock. Crit Care Med 13:451–453PubMedCrossRefGoogle Scholar
  15. 15.
    Reines HD, Cook JA, Halushka PV, et al (1982) Plasma thromboxane concentrations are raised in patients dying with septic shock. Lancet 2:174–175PubMedCrossRefGoogle Scholar
  16. 16.
    Fourrier F, Chopin C, Wallaert B, et al (1985) Compared evolution of plasma fibronectin and angio-converting enzyme levels in septic ARDS. Chest 87:191–195PubMedCrossRefGoogle Scholar
  17. 17.
    O’Connell MT, Becker DM, Steele BW, et al (1984) Plasma fibronectin in medical ICU patients. Crit Care Med 12:479–482PubMedCrossRefGoogle Scholar
  18. 18.
    Zinner SH, McCabe WR (1976) Effects of IgM and IgG antibody in patients with bacteremia due to gram-negative bacilli. J Infect Dis 133:37–45PubMedCrossRefGoogle Scholar
  19. 19.
    Pollack M, Huang AI, Prescott RK, et al (1984) Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to E. coli endotoxin core. J Clin Invest 72:1874–1881CrossRefGoogle Scholar
  20. 20.
    Girötti MJ, Menkes E, MacDonald J WD, et al (1984) Effects of immunization on cardiopulmonary alterations of gram-negative endotoxemia. J Appl Physiol 56:582–589PubMedGoogle Scholar
  21. 21.
    Ziegler EJ, McCutchan JA, Fierer J, et al (1982) Treatment of gram-negative bacteremia and shock with human antiserum to a mutant E. coli. N Engl J Med 307:1225–1230PubMedCrossRefGoogle Scholar
  22. 22.
    Lachman E, Pitsoe SB, Gaffin SL (1984) Anti-lipopolysaccharide immunotherapy in management of septic shock of obstetric and gynecological origin. Lancet 1:981–983PubMedCrossRefGoogle Scholar
  23. 23.
    Moore RD, Smith CR, Lietman PS (1984) The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 149:443–448PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • R. C. Bone
  • R. C. Brown

There are no affiliations available

Personalised recommendations